本帖隐藏的内容需要回复才可以浏览Published Online August 9 2012
Science DOI: 10.1126/science.1222908
Highly Conserved Protective Epitopes on Influenza B Viruses
Cyrille Dreyfus1,*, Nick S. Laursen1,2,*, Ted Kwaks3, David Zuijdgeest3, Reza Khayat1, Damian C. Ekiert1,†, Jeong Hyun Lee1, Zoltan Metlagel1,‡, Miriam V. Bujny3, Mandy Jongeneelen3, Remko van der Vlugt3, Mohammed Lamrani3, Hans J. W. M. Korse3, Eric Geelen3, Özcan Sahin3, Martijn Sieuwerts3, Just P. J. Brakenhoff3, Ronald Vogels3, Olive T. W. Li4, Leo L. M. Poon4, Malik Peiris4, Wouter Koudstaal3, Andrew B. Ward1, Ian A. Wilson1,5,§, Jaap Goudsmit3,§, Robert H. E. Friesen3
［Abstract］Identification of broadly neutralizing antibodies against influenza A viruses has raised hopes for the development of monoclonal antibody–based immunotherapy and “universal” vaccines for influenza. However, a significant part of the annual flu burden is caused by two cocirculating, antigenically distinct lineages of influenza B viruses. Here, we report human monoclonal antibodies, CR8033, CR8071, and CR9114, that protect mice against lethal challenge from both lineages. Antibodies CR8033 and CR8071 recognize distinct conserved epitopes in the head region of the influenza B hemagglutinin (HA), whereas CR9114 binds a conserved epitope in the HA stem and protects against lethal challenge with influenza A and B viruses. These antibodies may inform on development of monoclonal antibody–based treatments and a universal flu vaccine for all influenza A and B viruses.